Oliva Therapeutics to Partner with Rio Biopharmaceuticals
This collaboration is the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals.
Oliva Therapeutics announced on June 13, 2023 a long-term partnership with Rio Biopharmaceuticals for the exclusive North American supply and distribution rights to a multi-product portfolio. This collaboration is the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals, according to the company press release.
“Oliva Therapeutics is excited and honored to have been selected as the exclusive partner for this unique and high-value portfolio of products,” said Daniel Akeson, CEO of Oliva Therapeutics, in a press release. “The Rio Biopharmaceuticals team and EMS have developed an incredible global infrastructure with a thoughtful portfolio that offers quality and value.”
Daniel Salazar, CEO of Rio Biopharmaceuticals, added that Rio Biopharmaceuticals and the EMS Pharma organization have a tremendous history of delivering high-quality, cost-conscious pharmaceuticals throughout the world. “Entering into the North American markets represents an important step in our growth and evolution, and partnering with a family-owned company in Oliva Therapeutics ensures that our culture and values are well represented,” he said in a press release.
Source: Oliva Therapeutics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
